Found: 39
Select item for more details and to access through your institution.
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
- Published in:
- Supportive Care in Cancer, 2021, v. 29, n. 1, p. 117, doi. 10.1007/s00520-020-05459-0
- By:
- Publication type:
- Article
Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1247879
- By:
- Publication type:
- Article
Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-24457-2
- By:
- Publication type:
- Article
High prevalence of lung cancer in a surgical cohort of lung cancer patients a decade after smoking cessation.
- Published in:
- Journal of Cardiothoracic Surgery, 2011, v. 6, n. 1, p. 19, doi. 10.1186/1749-8090-6-19
- By:
- Publication type:
- Article
The Patient Journey in Non-Small-Cell Lung Cancer: An Overview.
- Published in:
- Conquer, 2020, v. 6, n. 4, p. 19
- By:
- Publication type:
- Article
Biomarker Testing in Non-Small-Cell Lung Cancer: A Guide for Patients.
- Published in:
- Conquer, 2020, v. 6, n. 3, p. 52
- By:
- Publication type:
- Article
Treatment of Non-Small-Cell Lung Cancer: A Guide for Patients.
- Published in:
- Conquer, 2020, v. 6, n. 2, p. 48
- By:
- Publication type:
- Article
Staging of Non-Small-Cell Lung Cancer: A Guide for Patients.
- Published in:
- Conquer, 2020, v. 6, n. 1, p. 48
- By:
- Publication type:
- Article
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC).
- Published in:
- Clinical Lung Cancer, 2021, v. 22, n. 4, p. 301, doi. 10.1016/j.cllc.2021.02.010
- By:
- Publication type:
- Article
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC).
- Published in:
- 2018
- By:
- Publication type:
- journal article
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation- Positive Metastatic Non—Small-Cell Lung Cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.
- Published in:
- 2015
- By:
- Publication type:
- journal article
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed- Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer.
- Published in:
- Clinical Lung Cancer, 2015, v. 16, n. 3, p. 200, doi. 10.1016/j.cllc.2014.11.004
- By:
- Publication type:
- Article
A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non– Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment...
- Published in:
- Clinical Lung Cancer, 2012, v. 13, n. 6, p. 505, doi. 10.1016/j.cllc.2012.06.007
- By:
- Publication type:
- Article
Label-free enumeration, collection and downstream cytological and cytogenetic analysis of circulating tumor cells.
- Published in:
- Scientific Reports, 2016, p. 35474, doi. 10.1038/srep35474
- By:
- Publication type:
- Article
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
- Published in:
- Drugs, 2021, v. 81, n. 5, p. 547, doi. 10.1007/s40265-021-01477-2
- By:
- Publication type:
- Article
Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Using Immune Checkpoint Inhibitors in Lung Cancer... includes discussion.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 8, p. 713
- By:
- Publication type:
- Article
Management of Small-Cell Lung Cancer: Time to Move Forward.
- Published in:
- Oncology (08909091), 2010, v. 24, n. 11, p. 1043
- By:
- Publication type:
- Article
Uncertainty and psychological adjustment in patients with lung cancer.
- Published in:
- Psycho-Oncology, 2013, v. 22, n. 6, p. 1396, doi. 10.1002/pon.3155
- By:
- Publication type:
- Article
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 2, p. 339, doi. 10.1007/s00262-022-03252-y
- By:
- Publication type:
- Article
Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review.
- Published in:
- Frontiers in Immunology, 2020, v. 11, p. 1, doi. 10.3389/fimmu.2020.01036
- By:
- Publication type:
- Article
Highlights In Non-Small Cell Lung Cancer From the IASLC 2023 World Conference on Lung Cancer: Commentary.
- Published in:
- Clinical Advances in Hematology & Oncology, 2023, v. 21, p. 13
- By:
- Publication type:
- Article
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00665-z
- By:
- Publication type:
- Article
Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists.
- Published in:
- Cancer Medicine, 2022, v. 11, n. 2, p. 530, doi. 10.1002/cam4.4459
- By:
- Publication type:
- Article
The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
- Published in:
- 2017
- By:
- Publication type:
- Editorial
In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies.
- Published in:
- International Journal of Cancer, 2007, v. 121, n. 3, p. 675, doi. 10.1002/ijc.22723
- By:
- Publication type:
- Article
<sup>18</sup>F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib.
- Published in:
- Journal of Nuclear Medicine, 2011, v. 52, n. 11, p. 1684, doi. 10.2967/jnumed.111.095257
- By:
- Publication type:
- Article
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis.
- Published in:
- 2015
- By:
- Publication type:
- Case Study
A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer.
- Published in:
- OncoTargets & Therapy, 2016, v. 9, p. 7275, doi. 10.2147/OTT.S109186
- By:
- Publication type:
- Article
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 311, n. 19, p. 1998, doi. 10.1001/jama.2014.3741
- By:
- Publication type:
- Article
Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY.
- Published in:
- Cancer Science, 2020, v. 111, n. 12, p. 4510, doi. 10.1111/cas.14655
- By:
- Publication type:
- Article
Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients.
- Published in:
- Frontiers in Oncology, 2020, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.572895
- By:
- Publication type:
- Article
RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
- Published in:
- Drug Safety, 2022, v. 45, n. 1, p. 45, doi. 10.1007/s40264-021-01127-2
- By:
- Publication type:
- Article